---
title: "Shattuck Labs to Join Piper Sandler Virtual Novel Targets in Immunology Symposium"
type: "News"
locale: "zh-HK"
url: "https://longbridge.com/zh-HK/news/275132543.md"
datetime: "2026-02-06T13:30:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/275132543.md)
  - [en](https://longbridge.com/en/news/275132543.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/275132543.md)
---

> 支持的語言: [简体中文](https://longbridge.com/zh-CN/news/275132543.md) | [English](https://longbridge.com/en/news/275132543.md)


# Shattuck Labs to Join Piper Sandler Virtual Novel Targets in Immunology Symposium

Shattuck Labs Inc., a clinical-stage biotechnology company specializing in novel therapeutics for inflammatory and immune-mediated diseases, will participate in a fireside chat at the Piper Sandler Virtual Novel Targets in Immunology Symposium on February 12, 2026, at 2:00 PM ET. The company’s CEO Taylor Schreiber, M.D., Ph.D., CFO Andrew R. Neill, and Vice President of Clinical Development Michael Choi, M.D., will represent Shattuck Labs during the event. A replay of the prerecorded presentation will be available on the Events and Presentations section of Shattuck Labs’ website starting at 2:00 PM ET on February 12, 2026, and will be archived for up to 30 days following the presentation date. A webcast link is provided: HERE. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shattuck Labs Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9650089-en) on February 06, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)

### 相關股票

- [Invesco Nasdaq Biotechnology ETF (IBBQ.US)](https://longbridge.com/zh-HK/quote/IBBQ.US.md)
- [Invesco Biotechnology & Genome ETF (PBE.US)](https://longbridge.com/zh-HK/quote/PBE.US.md)
- [ALPS Medical Breakthrough (SBIO.US)](https://longbridge.com/zh-HK/quote/SBIO.US.md)
- [VanEck Biotech ETF (BBH.US)](https://longbridge.com/zh-HK/quote/BBH.US.md)
- [Proshares Ultra Nasdaq Biotech (BIB.US)](https://longbridge.com/zh-HK/quote/BIB.US.md)
- [iShares Biotechnology ETF (IBB.US)](https://longbridge.com/zh-HK/quote/IBB.US.md)
- [First Trust NYSE Arca Biotech Index Fd (FBT.US)](https://longbridge.com/zh-HK/quote/FBT.US.md)
- [Shattuck Labs (STTK.US)](https://longbridge.com/zh-HK/quote/STTK.US.md)
- [SPDR S&P Biotech (XBI.US)](https://longbridge.com/zh-HK/quote/XBI.US.md)

## 相關資訊與研究

- [BUZZ-MiNK Therapeutics rises as it wins funding for child cancer cell therapy](https://longbridge.com/zh-HK/news/278530484.md)
- [FDA approves GSK’s Wellcovorin for cerebral folate deficiency](https://longbridge.com/zh-HK/news/278697677.md)
- [BioMarin Pharmaceutical Highlights Growth Plan, VOXZOGO Milestones, and Amicus Deal at Conference](https://longbridge.com/zh-HK/news/279015256.md)
- [Allogene Therapeutics Faces Trial Setback as ALLO-647 Halt Raises Lymphodepletion and Regulatory Timeline Risks](https://longbridge.com/zh-HK/news/279113385.md)
- [AbbVie reports topline data from Phase I ABBV-295 trial](https://longbridge.com/zh-HK/news/278540526.md)